FAM187B

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, FAM187B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM187B data layer compared with 20 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher FAM187B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM187B expression acts as an unfavorable survival marker.

THCA are the cancer types where FAM187B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
THCADFSMedianAll0.0490.841<.00124view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

FAM187B–THCA (DFS)

Kaplan–Meier survival curve for FAM187B mutant vs wild-type samples in THCA.

Open the THCA breakdown →

Exploration